Celgene Settlement With Actavis Allows Abraxane Generics In 2022

Celgene settles Abraxane patent litigation and inter partes review with Teva's Actavis, allowing a generic to enter the market on March 31, 2022 – about four years before the drug's key patents expire.

Celgene Corp. revealed late on Jan. 26 that it entered into a settlement with Actavis LLC, part of Teva Pharmaceutical Industries Ltd., to end ongoing patent litigation and an inter partes review (IPR) via an agreement that will allow distribution of generic Abraxane in 2022.

The settlement ends a lawsuit Celgene filed against Actavis in 2016 in US District Court for the District of New Jersey and an IPR proceeding initiated by Actavis in 2017 that was pending at the US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB)

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

05 May 2025

• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

05 May 2025

• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.